

Fat-separated T1 mapping for liver function analysis on gadoxetic acid-enhanced MR imaging: 2D two-point Dixon Look-Locker inversion recovery sequence for differentiation of Child-Pugh class B/C from Child-Pugh class A/chronic liver disease

Ye Rin Hwang¹, Miri Seo², Ute Goerke³, Mahesh Bharath Keerthivasan⁴, MunYoung Paek⁵, Seong Jin Park¹, Myung-Won You¹^

¹Department of Radiology, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea; ²Department of Medicine, Kyung Hee University College of Medicine, Seoul, Republic of Korea; ³Siemens Healthineers, Tucson, AZ, USA; ⁴Siemens Healthineers, New York, NY, USA; ⁵Siemens Healthineers, Seoul, Republic of Korea

Contributions: (I) Conception and design: MW You, M Paek, SJ Park; (II) Administrative support: M Seo, U Goerke, MB Keerthivasan, M Paek; (III) Provision of study materials or patients: MW You, YR Hwang, M Seo, SJ Park; (IV) Collection and assembly of data: YR Hwang, MW You, M Seo; (V) Data analysis and interpretation: YR Hwang, M Seo, MW You, M Paek, U Goerke, MB Keerthivasan; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Myung-Won You, MD. Department of Radiology, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Kyungheedae-ro 23, Dongdaemun-gu, Seoul 02447, Republic of Korea. Email: funfun2020@khu.ac.kr.

Background: T1 relaxation time is a tissue-specific parameter that correlates with liver fibrosis, and can be a valuable tool for detecting and staging of liver disease. However, T1 can be affected by histological factors such as fat, so it is necessary to study the effects of hepatic steatosis when assessing liver function and fibrosis. The purpose of this study is to investigate the fat separation effect of T1 mapping using Dixon watermap Look-Locker inversion recovery (LLIR) in the assessment of liver function on gadoxetic acid (GA)-enhanced magnetic resonance imaging (MRI).

Methods: A total of 226 patients who underwent 3T MRI, including a 2D Dixon fat-separated LLIR T1 mapping, were included retrospectively. Two independent readers measured pre- and post-contrast T1 relaxation times (preT1 and postT1) on composite and watermap T1, and reproducibility was evaluated. The correlation of T1 parameters with biochemical and imaging biomarkers of liver function were assessed on both composite and Dixon watermap images; T1 parameters included averaged preT1, postT1 values, changes between pre- and post-T1liver (deltaT1) and adjusted T1liver (postT1liver – T1spleen/T1spleen). And the diagnostic performance of T1 parameters for Child-Pugh (CP) class was also evaluated.

Results: Inter- and intra-reader reproducibility showed almost perfect agreement [intraclass correlation coefficient (ICC) 0.929–0.999]. Watermap preT1 (r=-0.125, P=0.068) and watermap deltaT1 (r=0.055, P=0.414) showed loss of correlation with fat fraction (FF) compared with preT1 and deltaT1. Albumin, total bilirubin (TB), hepatobiliary enhancement grade, and R2* (1/T2*), were significantly associated with watermap T1, eliminating the effect of FF. Area under the curve (AUC) of preT1, watermap preT1, deltaT1, postT1, watermap adjusted T1, and adjusted T1 were 0.681 [standard error (SE) 0.114], 0.748 (SE 0.098), 0.921 (SE 0.033), 0.951 (SE 0.018), 0.950 (SE 0.018), and 0.973 (SE 0.013) respectively, for differentiating patient with CP class B/C from CP-A/chronic liver disease (CLD).

Conclusions: T1 values using Dixon watermap LLIR eliminated the confounding effect of fat and showed

[^] ORCID: 0000-0001-6262-5784.

the correlation with serological and imaging markers of liver function. Adjusted T1, watermap adjusted T1, and postT1 showed the highest diagnostic performance in differentiating CP class B/C from CP-A/CLD.

Keywords: T1 map; magnetic resonance imaging (MRI); Look-Locker inversion recovery (LLIR); hepatic steatosis; liver function estimation

Submitted Apr 21, 2024. Accepted for publication Dec 20, 2024. Published online Feb 26, 2025. doi: 10.21037/qims-24-805

View this article at: https://dx.doi.org/10.21037/qims-24-805

Introduction

Evaluation of liver function in chronic liver disease (CLD) or liver cirrhosis (LC) is crucial for therapeutic decision-making and the prediction of prognosis (1).

Several methods are available for assessing hepatic functional capacity. Serologic tests, including liver enzymes, bilirubin, albumin, prothrombin time, and fibrogenesis-related biomarkers, represent simple yet conventional non-invasive methods. Hepatic parenchymal enhancement on gadoxetic acid (GA)-enhanced magnetic resonance imaging (MRI) during the hepatobiliary phase (HBP) can accurately reflect hepatic function and has been studied as an alternative to indocyanine green kinetics and hepatobiliary scintigraphy (2-5). Visual assessment of HBP enhancement has been studied using categorical grading (6,7) whereas quantitative measurement of HBP enhancement can be confounded by several imaging parameters and technical factors (6,8).

Hepatic T1 relaxation time measured by magnetic resonance (MR) relaxometry is a tissue-specific parameter that correlates with the hepatic concentration of GA or hepatic fibrosis, and increases with the progression of cirrhosis, showing associations with other functional parameters (8-11). T1 mapping serves as a tool that can be implemented without additional hardware, and is not affected by an individual's body habitus, including factors like obesity or ascites. However, T1 values can be influenced by histological components other than fibrosis, such as fat, iron, edema, and inflammation (12). Previous studies have shown that the T1 values decrease with iron overload and increase in the presence of edema and inflammation (12-18). In addition, T1 varies with echo time in the presence of liver fat (19). Alteration in fat content in the liver or coexisting nonalcoholic fatty liver disease is relatively common in patients with CLD or LC; therefore, it is important to eliminate the influence of fat tissue for a precise quantitative assessment of hepatic function using T1

mapping.

The purpose of this study was to obtain fat-separated T1 values using a Look-Locker inversion recovery (LLIR) with Dixon sequence on GA-enhanced MRI, and to investigate the role of Dixon watermap T1 for the assessment of hepatic function. We present this article in accordance with the STROBE reporting checklist (available at https://qims.amegroups.com/article/view/10.21037/qims-24-805/rc).

Methods

Patients

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the institutional review board of Kyung Hee University Hospital (No. 2023-12-032). Individual consent for this retrospective study was waived. Between March 2021 and June 2022, 699 patients who underwent GAenhanced liver MRI, including the Dixon-coupled LLIR sequence (prototype, Siemens Healthineers, Erlangen, Germany), were enrolled in Kyung Hee University Hospital retrospectively. Among them, 156 patients were excluded for the following reasons: (I) absence of the Q-Dixon proton density fat fraction (PDFF) map sequence (n=71); (II) inability to define the hepatic contour due to poor image quality or incomplete coverage of the whole liver (n=82); and (III) non-measurable due to focal hepatic lesions (n=3). The remaining 543 patients were divided into two groups using a fat fraction (FF) cutoff 6.4% [according to previously determined cut-off for defining fatty liver (FL) (20)], and 67 patients were included in the FL group (FF \geq 6.4%). To match the numbers between the fatty and non-fatty groups, random selection was performed among the 476 patients; 159 patients were included as the non-fatty liver (NFL) group (male-to-female ratio, 168:58, Figure 1). For these patients, the etiology of the underlying liver disease, serum albumin, total bilirubin




Figure 1 Patient selection. *, total 226 patients were analyzed for correlation between liver T1 and fat fraction and regression analysis for liver T1 using clinical data. MRI, magnetic resonance imaging; FF, fat fraction.

(TB), prothrombin time, and aspartate aminotransferase/ alanine aminotransferase levels were checked by reviewing electronic medical records. The Child-Pugh (CP) class was determined using a combination of clinical and imaging findings.

MR image acquisition

All imaging was performed using a 3T MRI (MAGNETOM Vida; Siemens Healthineers) with a 30-channel phased-array body coil. With a 6-point multi-echo Dixon volumetric interpolated breath-hold examination sequence (q-Dixon), the T2* corrected PDFF map and additional R2* map were automatically generated on the scanner. The scan parameters were as follows: echo time (TE), 0.9/1.77/2.64/3.51/4.38/5.25 ms; repetition time (TR), 6.3 ms; flip angle 3°; field-of-view (FOV), 440×303 mm²; matrix 128×88; slice thickness 3 mm; number of slices 60; acceleration factor 2×2; scan time 10 s.

T1 maps were obtained using LLIR (work in progress) sequences in two types; one is a composite T1 map without coupling with Dixon, and the other is a Dixon T1 map that allows obtaining a T1 map with fat and water separated. After the non-selective inversion pulse, a single-shot 2-dimensional spoiled fast low-angle shot readout for Look-Locker sampling were used to continuously sample the T1 magnetization recovery curve. Multiple inversion time

(TI) images are then processed using a pixel-wise three parameter nonlinear least-squares fitting to estimate the T1 map (21).

Both composite and Dixon T1 maps were acquired twice, before and 20 minutes after GA administration, and one slice covering the largest area of liver parenchyma was acquired for scanning during expiratory breathholding. The scan parameters for the Dixon T1 maps were as follows: TR/TE1/TE2 3.5/1.23/2.46 ms; flip angle, 8 degrees; FOV 350 mm; acquisition matrix, 128×64; acceleration factor, 2; slice thickness, 6 mm; receiver bandwidth 1,500 Hz/pixel; scan time 15 s. Composite T1 maps were acquired with single echo (TR/TE 3 ms/1.3 ms) and the other parameters were identical. For both composite and Dixon T1 map, a total of 30 images with different effective TI were acquired at 155.32 ms intervals, and the acquired TI range was 86.16-4,590.44 ms after a non-selective inversion pulse during single breath-hold. In the Dixon T1 map (hereafter, watermap T1), images were acquired at two echo times selected as out-phase and in-phase after the inversion recovery pulse. From these two corresponding inverted images, a fat-only and a water-only T1 map were calculated by the two-point Dixon algorithm (22,23).

Image analysis

For measurement of T1 values, two independent reviewers




Figure 2 Representative measurement of T1 relaxation times, fat fraction, and R2* value. (A) Free-hand drawn ROI of liver on preenhanced T1 map. (B) Free-hand drawn ROI of liver and spleen on post-enhanced T1 map. (C) Measurement of fat fraction with circular ROIs on each nine-segment liver on proton density fat fraction map. (D) Free-hand drawn ROI covering the whole liver on R2* map. SD, standard deviation of pixel values within the ROI; AAD, average absolute deviation of pixel values within the ROI; W, horizontal length of the ROI; H, vertical length of the ROI; ROI, region of interest.

(Y.R.H., 5 years of experience in MR; M.S., 1-year of experience in MR) drew free-hand regions of interest (ROIs) on each slice of conventional pre-enhanced and post-enhanced T1 and watermap preT1 and postT1 maps (mean area, 7,743.37 mm²) blinded to clinical data and CP classes. ROIs were placed on the preT1 maps, and then copied and pasted onto the watermap preT1, postT1, and watermap postT1 maps. During the procedure, ROIs were adjusted according to the outer edge of the liver if the contour or level of the liver parenchyma did not match the original images. Focal lesions and major branches of hepatic vessels were carefully avoided. Two reviewers repeated the T1 measurement with a 2-week interval to assess reproducibility. The mean values of the ROIs were considered the representative T1 relaxation times of the liver and spleen (Figure 2). Two additional parameters were obtained; deltaT1 liver was defined as (preT1 postT1)/preT1 to assess the GA uptake by functioning

hepatocytes, and adjusted T1 was defined as [(postT1 liver – postT1 spleen)/postT1 spleen] to assess the degree of HBP enhancement without the effect of extracellular enhancement (8,24).

One of the two reviewers (Y.R.H.) drew two circular ROIs in each segment of liver on the Q-Dixon PDFF map, and the mean liver FF was calculated by averaging the FFs in a total of 18 ROIs in nine hepatic segments, according to the Couinaud classification (25). The same reviewer drew a freehand ROI with the same method of T1 measurement at the level where the liver appeared widest on the R2* map, to assess liver iron content.

The two reviewers visually assessed the liver morphology and liver parenchymal enhancement on HBP by consensus. Liver morphology was classified as normal, CLD, or LC according to previously defined criteria (26,27). HBP enhancement grade was categorized into three; Grade 1 marked hypointense vessels compared to liver parenchyma,

Grade 2 mild hypointense vessels, and Grade 3 isointense vessels (6,7).

Statistical analysis

Categorical data were presented as percentages, and numerical data were presented as means with standard deviations or medians with range, depending on whether or not they were Gaussian distributions. Comparison of clinical data and T1 parameters between the fatty and nonfatty groups was performed using the independent t-test. We used the *t*-test to compare two groups because the study population was greater than 30 in each group, although there were deviations from the normal distribution of the data. Reproducibility of T1 measurement was assessed using the intraclass correlation coefficient (ICC) >0.81, almost perfect, 0.61-0.81, substantial, 0.41-0.60, moderate, 0.21–0.40, fair; and Bland-Altman plots. The correlation between T1 parameters and liver FF was assessed using Pearson correlation coefficient (r), and multivariable linear regression analysis was performed to determine predictive factors for T1 parameters; the determination coefficient (R²) and adjusted R² were generated. All the results are presented with 95% confidence intervals and standard errors (SEs). Data are assumed to be missing at random, and all analysis was restricted to cases with complete data on all variables. We didn't use multiple imputation or sensitivity analysis to deal with missing data. Receiver operating characteristic (ROC) analysis was performed to assess the diagnostic performance of T1 values in differentiating CP class B/ C from CP class A/CLD. All statistical analyses were performed using Medcalc ver.20.111 (Medcalc software Ltd., Ostend, Belgium) and P<0.05 was defined as clinically significant.

Results

Clinical data and T1 parameters of included patients

Table 1 shows the descriptive data of the included patients. Mean age was 63.96±10.74, and most of the patients had viral B or viral C hepatitis (121/226, 53.5%). Mean preT1, postT1, and deltaT1 were 875.58±131.58 ms, 290.36±109.81 ms, and 0.668±0.113, respectively, and mean watermap preT1, watermap postT1, and watermap deltaT1 were 774.39±162.11 ms, 283.15±114.47 ms, and 0.625±0.149, respectively. Adjusted T1 and watermap adjusted T1 did not show any significant difference from

postT1 or fat correction effect.

Median liver FF was 3.22% (0.81–34.53%). Most of the patients had liver cirrhosis (61.9%, 140/226), 11.1% had CLD (25/226), and 26.9% had normal liver (61/226). Most of the patients with liver cirrhosis had CP class A (131/140), followed by CP class B (8/140) and CP class C (1/140). The majority of the patients showed normal HBP enhancement (72.5%, 161/226).

Comparison of T1 parameters between the FL and NFL groups

Mean preT1 was significantly longer in the FL group than that in the NFL group (926.38±133.48 vs. 855.26±125.58 ms, P<0.0001); however, watermap preT1 in the FL group decreased and showed no significant difference with that in the NFL group (736.66±177.11 vs. 789.33±153.83 ms, P=0.272) after fat separation. Likewise, deltaT1 in the FL group was significantly higher than that in the NFL group (0.70±0.01 vs. 0.66±0.12, P=0.033) while watermap deltaT1 in the FL group and the NFL group showed no significant difference (0.62±0.16 vs. 0.63±0.14, P=0.779). PostT1 showed no differences between the FL and NFL groups, as did watermap postT1 (P>0.05, Table 2).

Repeatability and reproducibility of the measurement of T1 values on T1 mapping

Interobserver and intraobserver agreements were assessed for T1 parameters and are presented in *Table 3* and *Figure 3*. All T1 parameters, including preT1, watermap preT1, postT1, and watermap postT1 showed almost perfect agreement (interobserver 0.980–0.995; Reader 1 0.998–0.999; Reader 2 0.929–0.996). Bland-Altman plot shows mean bias of preT1 4.8 ms [95% limit of agreement (LOA): –23.2 to 32.8], watermap preT1 –12.3 ms (95% LOA: –45.8 to 21.3), postT1 –7.4 ms (95% LOA: –30.4 to 15.6), and watermap postT1 –5 ms (95% LOA: –28.4 to 18.4) between the two reviewers.

Correlation between T1 parameters and fat fraction

Changes in the correlation between T1 parameters and FF after fat correction are presented in *Table 4* and *Figure 4*. PreT1 and deltaT1 showed significant positive correlations with FF (P<0.0001, 0.0002) while watermap preT1 and watermap deltaT1 showed no correlation with FF (P=0.068, 0.414). PostT1 showed no significant correlation with FF,

Table 1 Descriptive data (n=226)

Age (years) 63.96±10.74 Sex Male 168 (74.3) Female 58 (25.7) Underlying disease Viral B hepatitis 113 (50.0) Viral C hepatitis 8 (3.5) Alcoholic liver disease 37 (16.4) Non-alcoholic fatty liver disease 5 (2.2) NonB nonC hepatitis 8 (3.5) Unknown 55 (24.3) PreT1 (ms) 875.58±131.58 Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 290.36±109.81 Watermap deltaT1 0.668±0.113 Watermap adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7~392.3] Fat fraction (%) 3.22 [0.81~34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2-5.0] Aspartate aminotransferase (IU/L) 35 [12~426] Prothrombin time international normalized ratio 1.02 [0.85-1.91] Total bilirubin (mg/dL) 0.86 [0.21~35.62] Hepatobi	Table 1 Descriptive data (n=226) Patients' data	Values
Male 168 (74.3) Female 58 (25.7) Underlying disease Viral B hepatitis 113 (50.0) Viral C hepatitis 8 (3.5) Alcoholic liver disease 37 (16.4) Non-alcoholic fatty liver disease 5 (2.2) NonB nonC hepatitis 8 (3.5) Unknown 55 (24.3) PreT1 (ms) 875.58±131.58 Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7–392.3] Fat fraction (%) 3.22 [0.81–34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2–5.0] Aspartate aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio 1.02 [0.85–1.91] Total bilirubin (mg/dL) 0.86 [0.21–35.62]	Age (years)	63.96±10.74
Female 58 (25.7) Underlying disease Viral B hepatitis 113 (50.0) Viral C hepatitis 8 (3.5) Alcoholic liver disease 37 (16.4) Non-alcoholic fatty liver disease 5 (2.2) NonB nonC hepatitis 8 (3.5) Unknown 55 (24.3) PreT1 (ms) 875.58±131.58 Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7–392.3] Fat fraction (%) 3.22 [0.81–34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2–5.0] Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	Sex	
Underlying disease Viral B hepatitis 113 (50.0) Viral C hepatitis 8 (3.5) Alcoholic liver disease 37 (16.4) Non-alcoholic fatty liver disease 5 (2.2) NonB nonC hepatitis 8 (3.5) Unknown 55 (24.3) PreT1 (ms) 875.58±131.58 Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.676±0.128 Watermap adjusted T1 0.676±0.128 Alanine aminotransferase (lU/L) 27 (6-368) Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2-5.0] Aspartate aminotransferase (lU/L) 27 [6-368] Aspartate aminotransferase (lU/L) 35 [12-426] Prothrombin time international normalized ratio 1.02 [0.85-1.91] Total bilirubin (mg/dL) 0.86 [0.21-35.62]	Male	168 (74.3)
Viral B hepatitis 113 (50.0) Viral C hepatitis 8 (3.5) Alcoholic liver disease 37 (16.4) Non-alcoholic fatty liver disease 5 (2.2) NonB nonC hepatitis 8 (3.5) Unknown 55 (24.3) PreT1 (ms) 875.58±131.58 Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7~392.3] Fat fraction (%) 3.22 [0.81-34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2-5.0] Alanine aminotransferase (IU/L) 27 [6-368] Aspartate aminotransferase (IU/L) 35 [12-426] Prothrombin time international normalized ratio 1.02 [0.85-1.91] Total bilirubin (mg/dL) 0.86 [0.21-35.62] Hepatobililiary phase enhancement grade <	Female	58 (25.7)
Viral C hepatitis 8 (3.5) Alcoholic liver disease 37 (16.4) Non-alcoholic fatty liver disease 5 (2.2) NonB nonC hepatitis 8 (3.5) Unknown 55 (24.3) PreT1 (ms) 875.58±131.58 Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7−392.3] Fat fraction (%) 3.22 [0.81−34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2−5.0] Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio 1.02 [0.85–1.91] Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade 38 (17.1) Grade 2: mild hypointense vessel 161 (72.5) Grade 2: mild hypointense vessel 23 (10.4) Liver morphology	Underlying disease	
Alcoholic liver disease Non-alcoholic fatty liver disease 5 (2.2) NonB nonC hepatitis Unknown 55 (24.3) PreT1 (ms) 875.58±131.58 Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 R2* (s-1 Hz) Fat fraction (%) 3.22 [0.81-34.53] Spleen (cm) Albumin (g/dL) Alanine aminotransferase (IU/L) Alanine aminotransferase (IU/L) Prothrombin time international normalized ratio Total bilirubin (mg/dL) Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel Grade 2: mild hypointense vessel Grade 3: isointense vessel Chronic liver disease 25 (11.1)	Viral B hepatitis	113 (50.0)
Non-alcoholic fatty liver disease 5 (2.2) NonB nonC hepatitis 8 (3.5) Unknown 55 (24.3) PreT1 (ms) 875.58±131.58 Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7~392.3] Fat fraction (%) 3.22 [0.81-34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2-5.0] Alanine aminotransferase (IU/L) 27 [6-368] Aspartate aminotransferase (IU/L) 35 [12-426] Prothrombin time international normalized ratio 1.02 [0.85-1.91] Total bilirubin (mg/dL) 0.86 [0.21-35.62] Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel 161 (72.5) Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal	Viral C hepatitis	8 (3.5)
NonB nonC hepatitis 8 (3.5) Unknown 55 (24.3) PreT1 (ms) 875.58±131.58 Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7-392.3] Fat fraction (%) 3.22 [0.81-34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2-5.0] Alanine aminotransferase (IU/L) 27 [6-368] Aspartate aminotransferase (IU/L) 35 [12-426] Prothrombin time international normalized ratio 1.02 [0.85-1.91] Total bilirubin (mg/dL) 0.86 [0.21-35.62] Hepatobiliary phase enhancement grade 161 (72.5) Grade 1: marked hypointense vessel 38 (17.1) Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1) <td>Alcoholic liver disease</td> <td>37 (16.4)</td>	Alcoholic liver disease	37 (16.4)
Unknown 55 (24.3) PreT1 (ms) 875.58±131.58 Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s ⁻¹ Hz) 44.9 [12.7-392.3] Fat fraction (%) 3.22 [0.81-34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2-5.0] Alanine aminotransferase (IU/L) 27 [6-368] Aspartate aminotransferase (IU/L) 35 [12-426] Prothrombin time international normalized ratio 1.02 [0.85-1.91] Total bilirubin (mg/dL) 0.86 [0.21-35.62] Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel 38 (17.1) Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	Non-alcoholic fatty liver disease	5 (2.2)
PreT1 (ms) 875.58±131.58 Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7–392.3] Fat fraction (%) 3.22 [0.81–34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2–5.0] Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio 1.02 [0.85–1.91] Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade 161 (72.5) Grade 1: marked hypointense vessel 38 (17.1) Grade 2: mild hypointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	NonB nonC hepatitis	8 (3.5)
Watermap preT1 (ms) 774.39±162.11 PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7–392.3] Fat fraction (%) 3.22 [0.81–34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2–5.0] Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio 1.02 [0.85–1.91] Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade 38 (17.1) Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	Unknown	55 (24.3)
PostT1 (ms) 290.36±109.81 Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7-392.3] Fat fraction (%) 3.22 [0.81-34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2-5.0] Alanine aminotransferase (IU/L) 27 [6-368] Aspartate aminotransferase (IU/L) 35 [12-426] Prothrombin time international normalized ratio 1.02 [0.85-1.91] Total bilirubin (mg/dL) 0.86 [0.21-35.62] Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel 161 (72.5) Grade 2: mild hypointense vessel 38 (17.1) 33 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	PreT1 (ms)	875.58±131.58
Watermap postT1 (ms) 283.15±114.47 DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7–392.3] Fat fraction (%) 3.22 [0.81–34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2–5.0] Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio 1.02 [0.85–1.91] Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade 161 (72.5) Grade 1: marked hypointense vessel 38 (17.1) Grade 2: mild hypointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	Watermap preT1 (ms)	774.39±162.11
DeltaT1 0.668±0.113 Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s⁻¹ Hz) 44.9 [12.7–392.3] Fat fraction (%) 3.22 [0.81–34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2–5.0] Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio 1.02 [0.85–1.91] Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel 161 (72.5) Grade 2: mild hypointense vessel 38 (17.1) 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	PostT1 (ms)	290.36±109.81
Watermap deltaT1 0.625±0.149 Adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s ⁻¹ Hz) 44.9 [12.7–392.3] Fat fraction (%) 3.22 [0.81–34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2–5.0] Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio 1.02 [0.85–1.91] Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade 161 (72.5) Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	Watermap postT1 (ms)	283.15±114.47
Adjusted T1 0.676±0.128 Watermap adjusted T1 0.653±0.164 R2* (s ⁻¹ Hz) 44.9 [12.7–392.3] Fat fraction (%) 3.22 [0.81–34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2–5.0] Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel 161 (72.5) Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	DeltaT1	0.668±0.113
Watermap adjusted T1 0.653±0.164 R2* (s ⁻¹ Hz) 44.9 [12.7–392.3] Fat fraction (%) 3.22 [0.81–34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2–5.0] Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio 1.02 [0.85–1.91] Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade 161 (72.5) Grade 1: marked hypointense vessel 38 (17.1) Grade 2: mild hypointense vessel 23 (10.4) Liver morphology 61 (26.9) Chronic liver disease 25 (11.1)	Watermap deltaT1	0.625±0.149
R2* (s ⁻¹ Hz) 44.9 [12.7–392.3] Fat fraction (%) 3.22 [0.81–34.53] Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2–5.0] Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio 1.02 [0.85–1.91] Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade 38 (17.1) Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	Adjusted T1	0.676±0.128
Fat fraction (%) Spleen (cm) Albumin (g/dL) Alanine aminotransferase (IU/L) Aspartate aminotransferase (IU/L) Prothrombin time international normalized ratio Total bilirubin (mg/dL) Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel Grade 2: mild hypointense vessel Grade 3: isointense vessel Liver morphology Normal Chronic liver disease 3.22 [0.81–34.53] 3.22 [0.81–34.53] 3.22 [0.81–34.53] 6.34.53] 4.2 [2.2–5.0] 27 [6–368] 1.02 [0.85–1.91] 0.86 [0.21–35.62] 161 (72.5) 23 (10.4) 61 (26.9) 25 (11.1)	Watermap adjusted T1	0.653±0.164
Spleen (cm) 10.15±2.00 Albumin (g/dL) 4.2 [2.2–5.0] Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel 161 (72.5) Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	R2* (s ⁻¹ Hz)	44.9 [12.7–392.3]
Albumin (g/dL) Alanine aminotransferase (IU/L) Aspartate aminotransferase (IU/L) Prothrombin time international normalized ratio Total bilirubin (mg/dL) Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel Grade 2: mild hypointense vessel Grade 3: isointense vessel Liver morphology Normal Chronic liver disease 4.2 [2.2–5.0] 4.2 [2.2–5.0] 27 [6–368] 1.02 [0.85–1.91] 0.86 [0.21–35.62] 161 (72.5) 23 (17.1) 61 (26.9) 25 (11.1)	Fat fraction (%)	3.22 [0.81–34.53]
Alanine aminotransferase (IU/L) 27 [6–368] Aspartate aminotransferase (IU/L) 35 [12–426] Prothrombin time international normalized ratio Total bilirubin (mg/dL) 0.86 [0.21–35.62] Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel 161 (72.5) Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	Spleen (cm)	10.15±2.00
Aspartate aminotransferase (IU/L) Prothrombin time international normalized ratio Total bilirubin (mg/dL) Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel Grade 2: mild hypointense vessel Grade 3: isointense vessel Liver morphology Normal Chronic liver disease 10.02 [0.85–1.91] 0.86 [0.21–35.62] 161 (72.5) 28 (17.1) 29 (10.4)	Albumin (g/dL)	4.2 [2.2–5.0]
Prothrombin time international normalized ratio Total bilirubin (mg/dL) Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel Grade 2: mild hypointense vessel Grade 3: isointense vessel Liver morphology Normal Chronic liver disease 1.02 [0.85–1.91] 1.02	Alanine aminotransferase (IU/L)	27 [6–368]
normalized ratio Total bilirubin (mg/dL) Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel Grade 2: mild hypointense vessel Grade 3: isointense vessel Liver morphology Normal Chronic liver disease 0.86 [0.21–35.62] 161 (72.5) 28 (17.1) 29 (10.4) 10 (26.9) 20 (11.1)	Aspartate aminotransferase (IU/L)	35 [12–426]
Hepatobiliary phase enhancement grade Grade 1: marked hypointense vessel 161 (72.5) Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)		1.02 [0.85–1.91]
Grade 1: marked hypointense vessel 161 (72.5) Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	Total bilirubin (mg/dL)	0.86 [0.21–35.62]
Grade 2: mild hypointense vessel 38 (17.1) Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	Hepatobiliary phase enhancement grade	
Grade 3: isointense vessel 23 (10.4) Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	Grade 1: marked hypointense vessel	161 (72.5)
Liver morphology Normal 61 (26.9) Chronic liver disease 25 (11.1)	Grade 2: mild hypointense vessel	38 (17.1)
Normal 61 (26.9) Chronic liver disease 25 (11.1)	Grade 3: isointense vessel	23 (10.4)
Chronic liver disease 25 (11.1)	Liver morphology	
,	Normal	61 (26.9)
Liver cirrhosis 140 (61.9)	Chronic liver disease	25 (11.1)
	Liver cirrhosis	140 (61.9)

Table 1 (continued)

Table 1 (continued)

Patients' data	Values
CP class	
Normal/chronic liver disease	86 (38.1)
CP class A	131 (58.0)
CP class B	8 (3.5)
CP class C	1 (0.4)

Values are presented as mean ± SD, n (%) or median [range]. IU, international unit; CP, Child-Pugh; SD, standard deviation.

with or without fat correction.

Multivariate linear regression analyses for variables affecting liver T1

Tables 5-10 present the predictive factors for T1 values and the changes in related factors after fat correction. FF, R2* values, HBP enhancement grade, and TB were significant factors in predicting preT1, whereas R2* values and HBP enhancement grade were the only remaining factors in predicting watermap preT1. Similarly, FF, HBP enhancement grade, TB, and albumin were significant factors in predicting deltaT1, while FF was eliminated after fat correction. R2* values, HBP enhancement grade, and albumin were the significant factors in predicting both adjusted T1 and watermap adjusted T1, however FF was not the significant factors for both.

ROC curve analysis of liver T1 for diagnosing hepatic decompensation

Figure 5 shows the diagnostic performance of liver T1 in differentiating patients with CP classes of B/C from others. The area under the curve (AUC) of fat-separated watermap preT1 was slightly higher (0.748, SE 0.098) than that of preT1 (0.681, SE 0.114), although there was no statistically significant difference (P=0.098). The AUC of postT1 (0.951, SE 0.018) and deltaT1 (0.921, SE 0.033) were similar but slightly higher than watermap postT1 (0.925, SE 0.045) and watermap deltaT1 (0.866, SE 0.063), without statistically significant differences (P>0.05). Both adjusted T1 (0.973, SE 0.013) and watermap adjusted T1 (0.950, SE 0.018) showed the highest AUCs along with postT1 (0.951, SE 0.018), followed by watermap postT1 (0.925, SE 0.045) and deltaT1 (0.921, SE 0.033).

Table 2 Comparison of descriptive data between fatty liver (n=67) and non-fatty liver groups (n=159)

Patients' data	Fatty liver group (n=67)	Non-fatty liver group (n=159)	P value
PreT1 (ms)	926.38 (133.48)	855.26 (125.58)	<0.0001
Watermap preT1 (ms)	736.66 (177.11)	789.33 (153.83)	0.272
PostT1 (ms)	278.06 (96.12)	295.23 (114.71)	0.303
Watermap postT1 (ms)	265.2 1(71.11)	290.14 (126.94)	0.071
DeltaT1	0.70 (0.01)	0.66 (0.12)	0.033
Watermap deltaT1	0.62 (0.16)	0.63 (0.14)	0.779
Adjusted T1	0.70 (0.10)	0.67 (0.14)	0.110
Watermap adjusted T1	0.66 (0.15)	0.65 (0.169)	0.701
R2* (s ⁻¹ Hz)	62.8 (4.731)	53.0 (3.988)	0.116
Fat fraction (%)	10.81 (1.57)	2.76 (1.33)	<0.001
Albumin (g/dL)	4.29 (0.39)	4.06 (0.53)	0.001
ALT (IU/L)	38.6 (44.86)	33.8 (36.54)	0.404
AST (IU/L)	47.54 (51.38)	43.24 (39.12)	0.494
PT INR	1.03 (0.14)	1.04 (0.12)	0.490
Total bilirubin (mg/dL)	0.99 (0.60)	1.43 (3.21)	0.280

Values are presented as mean (SD). ALT, alanine aminotransferase; AST, aspartate aminotransferase; IU, international unit; PT INR, prothrombin time international normalized ratio; SD, standard deviation.

Table 3 Reproducibility and repeatability: interobserver and intraobserver agreement of T1 map parameters

Reproducibility and repeatability	Composite preT1 map	Watermap preT1	Composite postT1 map	Watermap postT1
Interobserver reproducibility	0.986 (0.964-0.989)	0.987 (0.984-0.989)	0.980 (0.975-0.984)	0.995 (0.994–0.996)
Repeatability				
Reader 1	0.998 (0.998-0.999)	0.999 (0.999–0.999)	0.999 (0.998-0.999)	0.999 (0.999–1.000)
Reader 2	0.979 (0.972-0.984)	0.996 (0.995–0.997)	0.929 (0.907-0.946)	0.986 (0.982-0.989)

Values are presented as ICC (95% CI). ICC, intraclass correlation coefficient; CI, confidence interval.

Discussion

Liver function assessment using MR images allows a multidimensional approach including hepatic morphologic changes, qualitative or semi-quantitative parenchymal signal intensity (SI) assessment in HBP, and T1 relaxometry. SI-based indices on GA-enhanced MR are known to be useful parameters for estimating liver function. It can be performed with visual assessment by grading or with more objective and quantitative assessment by ROI measurement of SI and calculation of liver-spleen contrast ratio. Several studies investigated and compared the correlation of GA-enhanced MR SI-based indices and T1 relaxometry parameters with liver function, and reported the superiority of T1 map (24,28-30). T1 mapping on GA-enhanced MR correlates with quantitative assessment of liver HBP enhancement. In addition, T1 relaxometry provides a non-invasive and quantitative assessment of liver function that can be obtained within a single breath hold and independent of GA enhancement.

In our study, preT1 and deltaT1 on Dixon watermap images demonstrated significant correlation with TB, albumin, and qualitative HBP enhancement grade with eliminated confounding effect of fat. Higashi *et al.* also reported the reduced effect of fat on T1 value using Dixon water images compared with in-phase and out-of-phase




Figure 3 Bland-Altman plots for liver T1 measurements showing interobserver variability between the two reviewers. (A) Mean bias of preT1 was 4.8 ms (95% LOA: -23.2 to 32.8) and (B) mean bias of watermap preT1 was -12.3 ms (95% LOA: -45.8 to 21.3). (C) Mean bias of postT1 was -7.4 ms (95% LOA: -30.4 to 15.6) and (D) mean bias of watermap postT1 was -5 ms (95% LOA: -28.4 to 18.4). SD, standard deviation; LOA, limits of agreement.

Table 4 Correlation between liver T1 parameters and fat fraction

T1 value	Fat fraction (%), r (95% CI)	P value
PreT1	0.277 (0.158 to 0.404)	<0.0001
Watermap preT1	-0.125 (-0.288 to 0.027)	0.068
PostT1	0.159 (-0.286 to -0.026)	0.018
Watermap postT1	0.153 (-0.280 to -0.019)	0.024
DeltaT1	0.245 (0.123 to 0.374)	0.0002
Watermap deltaT1	0.055 (-0.112 to 0.157)	0.414
Adjusted T1	0.134 (-0.006 to 0.268)	0.060
Watermap adjusted T1	0.06 (-0.075 to 0.203)	0.362

r, Pearson correlation coefficient; CI, confidence interval.

based T1 values (19). Our study further explored fatseparated T1 values in both pre- and post-GA-enhanced MR using Dixon-coupled LLIR, and found that the fat correction effect was more pronounced in watermap preT1 than postT1.

Previous studies have reported that fat influences liver T1 values; therefore, fat must be corrected when using T1 mapping (18,19,31,32). Composite preT1 without fat separation was generated using a single exponential fit, producing an apparent T1 from the different T1-values of the fat and water signals (19,33). Depending on the echo time, the composite T1 can be longer or shorter than the watermap T1 as the fat signal changes from being in-phase to out-of-phase to the water signal, according to the echo time changes (34). Ahn et al. demonstrated that the liver T1 value increases as the steatosis grade increases and correlates with the fat fraction (31), which is consistent with our study. The elevated T1 value in steatotic liver decreases with fat correction because hepatic steatosis is a common response to injury, and is therefore usually associated with edema and inflammation caused by various conditions such as alcohol, toxin, infection, or metabolic steatotic liver disease (18,35). As hepatic steatosis may coexist in patients with CLD or LC, T1 relaxometry using Dixon-coupled LLIR allows the isolated T1 measurement of the water fraction, and may be a useful quantitative biomarker for non-invasive assessment




Figure 4 Correlation between liver T1 and fat fractions. (A) Pre-enhanced T1 (ms) showed a positive correlation with fat fraction (r=0.277, 95% CI: 0.158 to 0.404), P<0.0001), whereas (B) watermap preT1 showed a loss of correlation with fat fraction (r=-0.125, 95% CI: -0.288 to 0.027, P=0.068). (C) DeltaT1 showed a positive correlation with fat fraction (r=0.245, 0.123 to 0.374, P=0.0002), however (D) watermap deltaT1 showed a loss of correlation with fat fraction (r=0.055, -0.112 to 0.157, P=0.414). CI, confidence interval.

Table 5 Multiple linear regression analysis to predict liver T1 parameters: model for preT1

Variables	Regression coefficient (standard error)	P value
Fat fraction (%)	10.710 (1.367)	<0.0001
R2* (s ⁻¹ Hz)	-1.962 (0.148)	<0.0001
HBP enhancement, grade (per grade)	59.254 (12.937)	<0.0001
AST (IU/L)	-0.113 (0.257)	0.662
ALT (IU/L)	0.554 (0.283)	0.052
PT INR	40.945 (51.918)	0.431
TB (mg/dL)	-9.418 (2.370)	0.0001
Albumin (g/dL)	-37.985 (15.431)	0.015
CP class (per score class)	11.446 (11.365)	0.315

The determination coefficient was R^2 =0.581, and the adjusted determination coefficient was R^2 a=0.565. HBP, hepatobiliary phase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IU, international unit; PT INR, prothrombin time international normalized ratio; TB, total bilirubin; CP, Child-Pugh.

Table 6 Multiple linear regression analysis to predict liver T1 parameters: model for watermap preT1

Variables	Regression coefficient (standard error)	P value
Fat fraction (%)	-2.376 (2.289)	0.301
R2* (s ⁻¹ Hz)	-1.759 (0.276)	< 0.0001
HBP enhancement, grade (per grade)	60.139 (21.594)	0.006
AST (IU/L)	-0.335 (0.429)	0.437
ALT (IU/L)	0.079 (0.473)	0.867
PT INR	116.265 (86.798)	0.182
TB (mg/dL)	-3.008 (3.959)	0.448
Albumin (g/dL)	-0.333 (25.772)	0.989
CP class (per score class)	2.968 (18.962)	0.876

The determination coefficient was R^2 =0.219, and the adjusted determination coefficient was R^2 a=0.184. HBP, hepatobiliary phase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IU, international unit; PT INR, prothrombin time international normalized ratio; TB, total bilirubin; CP, Child-Pugh.

Table 7 Multiple linear regression analysis to predict liver T1 parameters: model for deltaT1

Variables	Regression coefficient (standard error)	P value
Fat fraction (%)	0.005 (0.001)	<0.0001
R2* (s ⁻¹ Hz)	0.00004 (0.0001)	0.725
HBP enhancement, grade (per grade)	-0.073 (0.011)	<0.0001
AST (IU/L)	-0.0004 (0.0002)	0.069
ALT (IU/L)	0.0001 (0.0002)	0.498
PT INR	-0.077 (0.043)	0.077
TB (mg/dL)	-0.012 (0.002)	<0.0001
Albumin (g/dL)	0.031 (0.013)	0.018
CP class (per score class)	0.010 (0.009)	0.286

The determination coefficient was R^2 =0.627, and the adjusted determination coefficient was adjusted R^2 a=0.609. HBP, hepatobiliary phase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IU, international unit; PT INR, prothrombin time international normalized ratio; TB, total bilirubin; CP, Child-Pugh.

Table 9 Multiple linear regression analysis to predict liver T1 parameters: model for adjusted T1

Variables	Regression coefficient (standard error)	P value
Fat fraction (%)	0.002 (0.001)	0.164
R2* (s ⁻¹ Hz)	0.0005 (0.0002)	0.009
HBP enhancement, grade (per grade)	-0.104 (0.014)	<0.001
AST (IU/L)	0.00002 (0.0003)	0.929
ALT (IU/L)	-0.0002 (0.0003)	0.438
PT INR	-0.098 (0.055)	0.071
TB (mg/dL)	-0.006 (0.002)	0.023
Albumin (g/dL)	0.038 (0.017)	0.023
CP class (per score class)	-0.009 (0.012)	0.471

The determination coefficient was R^2 =0.552, and the adjusted determination coefficient was R^2 a=0.530. HBP, hepatobiliary phase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IU, international unit; PT INR, prothrombin time international normalized ratio; TB, total bilirubin; CP, Child-Pugh.

of liver function.

Many previous studies have reported that hepatic T1 mapping using MR relaxometry is associated with liver fibrosis (13), CP classes (10,29,36), esophageal varices (8),

Table 8 Multiple linear regression analysis to predict liver T1 parameters: model for watermap deltaT1

1	1	
Variables	Regression coefficient (standard error)	P value
Fat fraction (%)	-0.0001 (0.002)	0.918
R2* (s ⁻¹ Hz)	-0.00004 (0.0003)	0.875
HBP enhancement, grade (per grade)	-0.061 (0.018)	0.001
AST (IU/L)	-0.008 (0.0004)	0.028
ALT (IU/L)	0.0003 (0.0003)	0.445
PT INR	-0.042 (0.073)	0.570
TB (mg/dL)	-0.009 (0.003)	0.006
Albumin (g/dL)	0.060 (0.022)	0.006
CP class (per score class)	0.003 (0.016)	0.869

The determination coefficient was R^2 =0.373, and the adjusted determination coefficient was R^2 =0.344. HBP, hepatobiliary phase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IU, international unit; PT INR, prothrombin time international normalized ratio; TB, total bilirubin; CP, Child-Pugh.

Table 10 Multiple linear regression analysis to predict liver T1 parameters: model for watermap adjusted T1

Variables	Regression coefficient (standard error)	P value
Fat fraction (%)	-0.0001 (0.002)	0.954
R2* (s ⁻¹ Hz)	0.0005 (0.0002)	0.035
HBP enhancement, grade (per grade)	-0.099 (0.019)	<0.0001
AST (IU/L)	-0.0002 (0.0004)	0.646
ALT (IU/L)	-0.0004 (0.0004)	0.297
PT INR	-0.114 (0.077)	0.140
TB (mg/dL)	-0.002 (0.003)	0.490
Albumin (g/dL)	0.092 (0.023)	0.0001
CP class (per score class)	0.001 (0.017)	0.934

The determination coefficient was R^2 =0.476, and the adjusted determination coefficient was R^2 a=0.449. HBP, hepatobiliary phase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IU, international unit; PT INR, prothrombin time international normalized ratio; TB, total bilirubin; CP, Child-Pugh.

and hepatic insufficiency and decompensation (34,37). In our study, T1 parameters using Dixon-coupled LLIR can discriminate higher CP class group (B/C) from normal and lower CP class group (A) with favorable diagnostic




Figure 5 Receiver operating characteristics curve of liver T1 for differentiating patients with Child-Pugh class B/C from those with Child-Pugh class A/chronic liver disease. (A) The AUC of preT1 and watermap preT1 were 0.681 (SE 0.114) and 0.748 (SE 0.098) without significant difference (P=0.098). (B) The AUC of postT1 and watermap postT1 were 0.951 (SE 0.018) and 0.925 (SE 0.045), and there was no statistically significant difference (P=0.476). (C) The AUC of deltaT1 and watermap deltaT1 were 0.921 (SE 0.033) and 0.866 (SE 0.063), without significant difference (P=0.272). (D) The AUC of adjusted T1 and watermap adjusted T1 were 0.973 (SE 0.013) and 0.950 (SE 0.018) without significant difference (P=0.067). Overall, postT1, adjusted T1 and watermap adjusted T1 showed the highest diagnostic performance, followed by watermap postT1 and deltaT1. AUC, area under the curve; SE, standard error.

performance (AUC ranging 0.68–0.97). According to previous studies, pre- and postT1 were significantly prolonged with increasing CP class (9,38), as shown in our study. In addition, adjusted T1 and postT1 showed the highest diagnostic performance for advanced cirrhosis (CP class B/C), followed by deltaT1 and preT1, which is consistent with previous studies that reported the superior correlation effect of postT1 compared with preT1 (29,37,39). Both pre- and postT1 are associated with liver fibrosis and cirrhosis, however, the change in preT1 is rather nonspecific and may be influenced by other factors (11,40,41). On the other hand, postT1 is associated with preT1 and reflects decreased hepatic uptake of contrast

media due to decreased organic anion-transporting polypeptide 1, which is related to hepatocyte function. We studied T1 relaxometry in both pre- and post-enhanced scans and found that the fat separation effect was dominant on preT1 and deltaT1 while post-enhanced T1 parameters (postT1 and adjusted T1) showed little difference between composite and watermap T1 and were less affected by fat fraction. GA enhancement shortens the T1 relaxation time in the liver, which is similar to the T1 of subcutaneous and liver fat (371 ms at 3T) (33). The reduced difference between T1 and watermap T1 after contrast injection may be due to the similar range of fat T1 and watermap T1 after contrast injection. This may explain the less pronounced

fat-separation effect of postT1, as postT1 approaches a similar value to fat T1 itself.

PostT1 obtained at 20 minutes after GA-enhancement reflect HBP enhancement, and further enables quantitative measurement of liver parenchymal enhancement. SI measurement on HBP is simple and direct method to evaluate liver function, however it can be variable depending on several technical factors and scanning parameters (6,29). PostT1 can be a good complementary and quantitative tool for liver function assessment in one additional single breath-hold scan.

Recent studies have reported the effectiveness of fat separation for accurate assessment of liver T1 (19,32,42). Our study investigated the clinical application of fatseparated T1 using 2D two-point Dixon LLIR, and suggested that watermap T1 mapping can more accurately assess liver function and fibrosis with less influence of hepatic steatosis. Fellner et al. studied fat-separated T1 map using variable flip angle (VFA) sequence with Dixon water-fat separation and reported that the difference between in-phase T1 and water-only T1 correlated with fat fraction (32). We used Dixon watermap T1 LLIR, which is a prototype of fat-separated T1, and it was investigated for both pre- and post-GA-enhanced MR in this work. LLIR or modified LLIR is one of the actively used clinical technique for T1 mapping, and has several advantages in terms of speed, accuracy, and good reproducibility (42,43). It is timely efficient that is obtainable in a single breath hold, constant for image acquisition and analysis, less prone to B1 field inhomogeneity than VFA method, and less affected by field strength than SI measurement (8,19,37). Our Dixon watermap T1 LLIR can be a robust imaging biomarker for liver function assessment with elimination of the confounding effect of fat in addition to the advantages of LLIR compared to other T1 mapping such as VFA technique.

The intra- and inter-observer agreement for the measurement of T1 parameters was almost perfect, and mean bias of preT1 and water preT1 was within 13 ms, with a range of 95% LOA within 70 ms. Similar studies have reported good reproducibility of liver T1 measurements (31,44); however, there is a lack of data regarding reproducibility across vendors, field strengths, and temporal assessments. Future studies should investigate the thresholds for distinguishing true changes beyond the clinically acceptable range of reproducibility in T1 measurement to develop a more standardized imaging biomarker for liver function assessment.

Our study has several limitations. First, this was a retrospective study in which we selected the FL group with a predefined FF threshold, and there were several missing and incomplete clinical data. However, the reviewer who drew ROIs for liver fat measurement was blinded for the clinical information and the study results, and independent another author performed data comparison between FL and NFL groups. Second, the study cohort was heterogeneous and consisted of patients with normal livers, CLD, and LC. We consecutively collected MR exam with Dixon LLIR sequence for T1 mapping regardless of etiology and indication for liver MR. Third, liver function was assessed using laboratory data only. We did not perform MR elastography or biopsy to evaluate liver fibrosis. However, we aimed to develop an easily-obtainable and simple method to evaluate liver function without additional software implementation or invasive procedure. Fourth, only a small proportion of patients with CP class C were included, so the comparability between CP classes may be limited. Therefore, we combined CP class B and C as one group, and CP class A and CLD as another group to facilitate the comparability between the two groups. Fifth, ROIs from the composite preT1 map were copied and pasted onto the watermap T1 and postT1, so there could be errors in the fitting of the ROIs due to motion and different breath holding levels. However, the operator additionally adjusted the ROIs according to the outer edge of the liver in case of mismatch errors. Sixth, although R2* was a significant factor for all T1 parameters, we did not perform iron correction. Iron overload reduces T1 value and excess iron levels in the presence of fibrosis can lead to pseudo-normal T1. However, since our study population mostly showed iron level within normal limit (R2* 136/s > at 3T MR), we did not consider iron correction for T1 evaluation as shown in a previous study (45). Seventh, we did not evaluate clinical outcomes, such as the development of hepatic insufficiency or decompensation. Further longitudinal study to investigate whether T1 parameters can predict clinical outcome after follow-up would be recommended.

Conclusions

In conclusion, fat-separated T1 mapping using Dixon-coupled LLIR effectively eliminated the confounding effect of fat in preT1 and deltaT1. Dixon watermap T1 with or without GA enhancement correlated significantly with representative serologic and imaging biomarkers of liver function, and

adjusted T1 and postT1 showed superior diagnostic performance in differentiating advanced CP classes.

Acknowledgments

We are grateful for the nonfinancial technical support from Siemens Healthineers.

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://qims.amegroups.com/article/view/10.21037/qims-24-805/rc

Funding: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government 371 (Ministry of Science and ICT) (NRF-2022R1C1C1012477).

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-24-805/coif). M.P. is an employee of Siemens Healthineers, Korea. U.G. and M.B.K. are developers at Siemens Healthineers, USA. All authors report nonfinancial technical support from Siemens Healthineers. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the institutional review board of Kyung Hee University Hospital (No. 2023-12-032) for reviewing medical records. Individual consent for this retrospective study was waived.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the noncommercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

- Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
- Jang HJ, Min JH, Lee JE, Shin KS, Kim KH, Choi SY. Assessment of liver fibrosis with gadoxetic acid-enhanced MRI: comparisons with transient elastography, ElastPQ, and serologic fibrosis markers. Abdom Radiol (NY) 2019:44:2769-80.
- Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Gastroenterology 2018;154:1369-79.
- 4. Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol 2012;57:421-9.
- 5. Zhang W, Wang X, Miao Y, Hu C, Zhao W. Liver function correlates with liver-to-portal vein contrast ratio during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MR at 3 Tesla. Abdom Radiol (NY) 2018;43:2262-9.
- Bae KE, Kim SY, Lee SS, Kim KW, Won HJ, Shin YM, Kim PN, Lee MG. Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI. Dig Dis 2012;30:617-22.
- Bastati N, Wibmer A, Tamandl D, Einspieler H, Hodge JC, Poetter-Lang S, Rockenschaub S, Berlakovich GA, Trauner M, Herold C, Ba-Ssalamah A. Assessment of Orthotopic Liver Transplant Graft Survival on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters. Invest Radiol 2016;51:728-34.
- 8. Yoon JH, Lee JM, Paek M, Han JK, Choi BI. Quantitative assessment of hepatic function: modified look-locker inversion recovery (MOLLI) sequence for T1 mapping on Gd-EOB-DTPA-enhanced liver MR imaging. Eur Radiol 2016;26:1775-82.
- Cassinotto C, Feldis M, Vergniol J, Mouries A, Cochet H, Lapuyade B, Hocquelet A, Juanola E, Foucher J, Laurent F, De Ledinghen V. MR relaxometry in chronic liver diseases: Comparison of T1 mapping, T2 mapping, and diffusionweighted imaging for assessing cirrhosis diagnosis and severity. Eur J Radiol 2015;84:1459-65.
- 10. Heye T, Yang SR, Bock M, Brost S, Weigand K, Longerich T, Kauczor HU, Hosch W. MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. Eur Radiol 2012;22:1224-32.
- 11. Thomsen C, Christoffersen P, Henriksen O, Juhl E.

- Prolonged T1 in patients with liver cirrhosis: an in vivo MRI study. Magn Reson Imaging 1990;8:599-604.
- 12. Hamdy A, Kitagawa K, Ishida M, Sakuma H. Native Myocardial T1 Mapping, Are We There Yet? Int Heart J 2016;57:400-7.
- Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, Collier JD, Booth JC, Schneider JE, Wang LM, Delaney DW, Fleming KA, Robson MD, Barnes E, Neubauer S. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 2014;60:69-77.
- 14. Henninger B, Kremser C, Rauch S, Eder R, Zoller H, Finkenstedt A, Michaely HJ, Schocke M. Evaluation of MR imaging with T1 and T2* mapping for the determination of hepatic iron overload. Eur Radiol 2012;22:2478-86.
- 15. von Ulmenstein S, Bogdanovic S, Honcharova-Biletska H, Blümel S, Deibel AR, Segna D, Jüngst C, Weber A, Kuntzen T, Gubler C, Reiner CS. Assessment of hepatic fibrosis and inflammation with look-locker T1 mapping and magnetic resonance elastography with histopathology as reference standard. Abdom Radiol (NY) 2022;47:3746-57.
- 16. Hoad CL, Palaniyappan N, Kaye P, Chernova Y, James MW, Costigan C, Austin A, Marciani L, Gowland PA, Guha IN, Francis ST, Aithal GP. A study of T1 relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. NMR Biomed 2015;28:706-14.
- Kellman P, Bandettini WP, Mancini C, Hammer-Hansen S, Hansen MS, Arai AE. Characterization of myocardial T1mapping bias caused by intramyocardial fat in inversion recovery and saturation recovery techniques. J Cardiovasc Magn Reson 2015;17:33.
- Mozes FE, Tunnicliffe EM, Pavlides M, Robson MD.
 Influence of fat on liver T1 measurements using modified Look-Locker inversion recovery (MOLLI) methods at 3T.
 J Magn Reson Imaging 2016;44:105-11.
- Higashi M, Tanabe M, Yamane M, Keerthivasan MB, Imai H, Yonezawa T, Nakamura M, Ito K. Impact of fat on the apparent T1 value of the liver: assessment by water-only derived T1 mapping. Eur Radiol 2023;33:6844-51.
- 20. Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, Gamst AC, Middleton M, Brunt EM, Loomba R, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013;267:422-31.
- 21. Deichmann R. Fast high-resolution T1 mapping of the

- human brain. Magn Reson Med 2005;54:20-7.
- 22. Leporq B, Ratiney H, Pilleul F, Beuf O. Liver fat volume fraction quantification with fat and water T1 and T 2* estimation and accounting for NMR multiple components in patients with chronic liver disease at 1.5 and 3.0 T. Eur Radiol 2013;23:2175-86.
- 23. Mozes FE, Tunnicliffe EM, Moolla A, Marjot T, Levick CK, Pavlides M, Robson MD. Mapping tissue water T(1) in the liver using the MOLLI T(1) method in the presence of fat, iron and B(0) inhomogeneity. NMR Biomed 2019;32:e4030.
- Yamada A, Hara T, Li F, Fujinaga Y, Ueda K, Kadoya M, Doi K. Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology 2011;260:727-33.
- Strasberg SM, Belghiti J, Clavien PA, Gadzijev E, Garden JO, Lau WY, Makuuchi M, Strong RW. The Brisbane 2000 Terminology of Liver Anatomy and Resections. HPB 2000:2:333-9.
- 26. Yoon JH, Lee JM, Han JK, Choi BI. Shear wave elastography for liver stiffness measurement in clinical sonographic examinations: evaluation of intraobserver reproducibility, technical failure, and unreliable stiffness measurements. J Ultrasound Med 2014;33:437-47.
- 27. Kudo M, Zheng RQ, Kim SR, Okabe Y, Osaki Y, Iijima H, Itani T, Kasugai H, Kanematsu M, Ito K, Usuki N, Shimamatsu K, Kage M, Kojiro M. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology 2008;51 Suppl 1:17-26.
- 28. Haimerl M, Verloh N, Zeman F, Fellner C, Nickel D, Lang SA, Teufel A, Stroszczynski C, Wiggermann P. Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: Comparison between signal-intensity-based indices and T1 relaxometry. Sci Rep 2017;7:43347.
- Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, Kudo M, Kitagaki H, Murakami T. Estimation of liver function using T1 mapping on Gd-EOB-DTPAenhanced magnetic resonance imaging. Invest Radiol 2011;46:277-83.
- 30. Kamimura K, Fukukura Y, Yoneyama T, Takumi K, Tateyama A, Umanodan A, Shindo T, Kumagae Y, Ueno S, Koriyama C, Nakajo M. Quantitative evaluation of liver function with T1 relaxation time index on Gd-EOB-DTPA-enhanced MRI: comparison with signal intensitybased indices. J Magn Reson Imaging 2014;40:884-9.
- 31. Ahn JH, Yu JS, Park KS, Kang SH, Huh JH, Chang JS, Lee JH, Kim MY, Nickel MD, Kannengiesser S, Kim JY,

- Koh SB. Effect of hepatic steatosis on native T1 mapping of 3T magnetic resonance imaging in the assessment of T1 values for patients with non-alcoholic fatty liver disease. Magn Reson Imaging 2021;80:1-8.
- Fellner C, Nickel MD, Kannengiesser S, Verloh N, Stroszczynski C, Haimerl M, Luerken L. Water-Fat Separated T1 Mapping in the Liver and Correlation to Hepatic Fat Fraction. Diagnostics (Basel) 2023.
- Gold GE, Han E, Stainsby J, Wright G, Brittain J, Beaulieu C. Musculoskeletal MRI at 3.0 T: relaxation times and image contrast. AJR Am J Roentgenol 2004;183:343-51.
- 34. Yoon JH, Lee JM, Kim E, Okuaki T, Han JK. Quantitative Liver Function Analysis: Volumetric T1 Mapping with Fast Multisection B(1) Inhomogeneity Correction in Hepatocyte-specific Contrast-enhanced Liver MR Imaging. Radiology 2017;282:408-17.
- 35. Klaus JB, Goerke U, Klarhöfer M, Keerthivasan MB, Jung B, Berzigotti A, Ebner L, Roos J, Christe A, Obmann VC, Huber AT. MRI Dixon Fat-Corrected Look-Locker T1 Mapping for Quantification of Liver Fibrosis and Inflammation-A Comparison With the Non-Fat-Corrected Shortened Modified Look-Locker Inversion Recovery Technique. Invest Radiol 2024;59:754-60.
- Besa C, Bane O, Jajamovich G, Marchione J, Taouli B. 3D T1 relaxometry pre and post gadoxetic acid injection for the assessment of liver cirrhosis and liver function. Magn Reson Imaging 2015;33:1075-82.
- 37. Kim JE, Kim HO, Bae K, Choi DS, Nickel D. T1 mapping for liver function evaluation in gadoxetic acid-enhanced MR imaging: comparison of look-locker inversion recovery and B(1) inhomogeneity-corrected variable flip angle method. Eur Radiol 2019;29:3584-94.
- Haimerl M, Verloh N, Zeman F, Fellner C, Müller-Wille R, Schreyer AG, Stroszczynski C, Wiggermann P. Assessment of clinical signs of liver cirrhosis using T1

Cite this article as: Hwang YR, Seo M, Goerke U, Keerthivasan MB, Paek M, Park SJ, You MW. Fat-separated T1 mapping for liver function analysis on gadoxetic acid-enhanced MR imaging: 2D two-point Dixon Look-Locker inversion recovery sequence for differentiation of Child-Pugh class B/C from Child-Pugh class A/chronic liver disease. Quant Imaging Med Surg 2025;15(3):1753-1767. doi: 10.21037/qims-24-805

- mapping on Gd-EOB-DTPA-enhanced 3T MRI. PLoS One 2013;8:e85658.
- Haimerl M, Fuhrmann I, Poelsterl S, Fellner C, Nickel MD, Weigand K, Dahlke MH, Verloh N, Stroszczynski C, Wiggermann P. Gd-EOB-DTPA-enhanced T1 relaxometry for assessment of liver function determined by real-time (13)C-methacetin breath test. Eur Radiol 2018;28:3591-600.
- 40. Goldberg HI, Moss AA, Stark DD, McKerrow J, Engelstad B, Brito A. Hepatic cirrhosis: magnetic resonance imaging. Radiology 1984:153:737-9.
- 41. Stark DD, Bass NM, Moss AA, Bacon BR, McKerrow JH, Cann CE, Brito A, Goldberg HI. Nuclear magnetic resonance imaging of experimentally induced liver disease. Radiology 1983;148:743-51.
- 42. Le Y, Dale B, Akisik F, Koons K, Lin C. Improved T1, contrast concentration, and pharmacokinetic parameter quantification in the presence of fat with two-point Dixon for dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med 2016;75:1677-84.
- 43. Zhang YT, Yeung HN, Carson PL, Ellis JH. Experimental analysis of T1 imaging with a single-scan, multiple-point, inversion-recovery technique. Magn Reson Med 1992;25:337-43.
- 44. Meloni A, Carnevale A, Gaio P, Positano V, Passantino C, Pepe A, Barison A, Todiere G, Grigoratos C, Novani G, Pistoia L, Giganti M, Cademartiri F, Cossu A. Liver T1 and T2 mapping in a large cohort of healthy subjects: normal ranges and correlation with age and sex. MAGMA 2024;37:93-100.
- 45. Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, Collier J, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol 2016;64:308-15.